TICKERNERD
Menu
ENLVENLVHealthcare · Biotechnology

ENLV Stock Forecast: Enlivex Ltd. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.28
−9.48% on the day

The 1 Wall Street analysts covering Enlivex Ltd. hold a median 12-month price target of $80 — +28780.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.1M
Ticker Nerd rank
11 / 100
Median analyst target
$80
Analysts covering
1
Revenue$0.0
Operating income−$5.9M
Net income$1.2B
Free cash flow−$2.6M
Quarterly, 8 quarters to 31 Dec 2025 · latest quarter's figure shown
Total return, dividends reinvested
1W
−34.5%
1M
−75.0%
YTD
−97.4%
1Y
−98.4%
From 52W high
−98.5%
From 52W low
0.0%
$0
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enlivex Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Revisions
82
Volatility
60
Issuance
13
Growth
8
Accruals
8
Value
6
Quality
5
Momentum
2

Size (96): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26ENLVHigh $80Median $80Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $80Median $80High $80

The green dot is the last close — the median target sits +28780.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $80
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
7 Apr 2026HC Wainwright & Co.MaintainsBuy$13 → $20
7 Apr 2026HC Wainwright & Co.MaintainsBuy—
12 Jan 2026HC Wainwright & Co.MaintainsBuy—
24 Nov 2025D. Boral CapitalDowngradeHold—
29 Oct 2025D. Boral CapitalMaintainsBuy—
26 Sept 2025D. Boral CapitalMaintainsBuy—
12 Sept 2025D. Boral CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
22 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
29 July 2025D. Boral CapitalMaintainsBuy—
22 July 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025D. Boral CapitalMaintainsBuy—
24 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
7 Feb 2025D. Boral CapitalMaintainsBuy—
11 Dec 2024D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ENLV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Enlivex Ltd. returned −98.4% against +16.2% for the S&P 500, dividends included.

ENLV vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ENLVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Enlivex Ltd. (ENLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 76% of US stocks

Price / sales
—
Price / book
0.0×

Cheaper than 92% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
162.9%

Higher than 98% of US stocks

Return on assets
−0.6%

Higher than 41% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enlivex Ltd. (ENLV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enlivex Ltd. has a market value of $6.1M and an enterprise value of $17.2M.

  • Revenue in the twelve months to 31 Dec 2025: $0.0.

  • Net income over the same four quarters: $1.2B.

  • Free cash flow in the twelve months to 31 Dec 2025: −$10.5M, after $67K of capital spending.

  • Shares outstanding: 15.8M.

  • Trailing P/E: 0.0×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Enlivex Ltd. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2025 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ENLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENLVEnlivex Ltd.$6.1M
11
PPCBPropanc Biopharma, Inc.$4.6M
50
XBIOXenetic Biosciences, Inc.$4.8M
29
LIMNLiminatus Pharma, Inc.$5.0M
15
DRMADermata Therapeutics, Inc.$4.3M
28
LNAILunai Bioworks, Inc.$5.1M
34
PMCBPharmaCyte Biotech, Inc.$4.3M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enlivex Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENLV news & analysis

Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens

GlobeNewsWire · 22 Sept 2026neutral

Enlivex Ltd. announced the termination of a previously-announced financing that was payable in RAIN tokens. The company made the disclosure in a September 22, 2026 release from its Nes-Ziona, Israel headquarters.

Why it matters — ENLV watchers would follow this development because the cancellation of the financing arrangement affects the company's stated funding plans and its prior capital-raising commitments.

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks Investment Research · 1 Sept 2026positive

Enlivex Ltd. (ENLV) has formed a hammer chart pattern, indicating the stock may have found support after recent losses. Zacks Investment Research notes the pattern suggests the price could have stabilized following its decline.

Why it matters — A hammer chart pattern signals potential technical support for ENLV, which watchers may view as a possible turning point after recent value declines.

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

GlobeNewsWire · 30 July 2026positive

Enlivex reported that trading volume on its Rain protocol reached $860 million as of July 29, 2026, representing 622% month-over-month growth in July compared to June.

Why it matters — The Rain protocol's trading metrics are part of Enlivex's treasury portfolio, so volume growth is directly relevant to the company's financial performance and valuation.

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

GlobeNewsWire · 29 July 2026positive

Enlivex announced that its management will host a live webinar on July 30, 2026 to discuss the company's private placement, Rain Protocol treasury strategy, and recent clinical progress for Allocetra™ including a new RMAT designation from the FDA.

Why it matters — The webinar will provide ENLV watchers with additional detail on the company's capital strategy, treasury strategy, and recent clinical milestones for Allocetra™.

Enlivex Announces $400,000,000 Private Placement

GlobeNewsWire · 28 July 2026positive

Enlivex announced a private placement of $400,000,000 of ordinary shares with a single institutional investor, at a per-share price of $5.00 for dollar-denominated subscriptions or $6.00 for subscriptions funded in RAIN tokens. The investor has elected to fund the purchase using RAIN tokens, with the option to change this election before closing.

Why it matters — The large capital raise provides Enlivex with substantial funding to execute its treasury strategy built around the Rain protocol while continuing to advance its clinical-stage immunotherapy Allocetra™.

FAQ

Frequently asked questions about ENLV stock

What is the ENLV stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Enlivex Ltd. have a median 12-month price target of $80, with estimates ranging from $80 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENLV stock a buy right now?

Of the 1 analysts covering Enlivex Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enlivex Ltd. 11 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENLV?

As at 8 Oct 2026, Enlivex Ltd. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will ENLV stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +28780.9% from the last close, and Ticker Nerd's factor model ranks Enlivex Ltd. 11 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENLV stock forecast for 2030?

No analyst covering Enlivex Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $80 over the next 12 months.

How has ENLV stock performed over the past year?

Enlivex Ltd. returned -98.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enlivex Ltd. do?

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment.

What is the latest news on ENLV?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens". Enlivex Ltd. announced the termination of a previously-announced financing that was payable in RAIN tokens. The company made the disclosure in a September 22, 2026 release from its Nes-Ziona, Israel headquarters.

Company

About Enlivex Ltd.

Enlivex Ltd. is a clinical-stage biotechnology company focused on macrophage reprogramming immunotherapy and inflammatory disease treatment. Its lead program, Allocetra, is designed to restore immune balance by reprogramming macrophages, with development efforts centered on conditions such as sepsis and osteoarthritis. The company’s current pipeline includes cell-based therapies for immune-related disorders and degenerative joint disease, reflecting its emphasis on novel approaches to immune modulation. Enlivex Ltd. operates from Ness Ziona, Israel, and serves the healthcare and biopharmaceutical markets through research, clinical development, and therapeutic innovation. The company’s role in the market is to advance experimental treatments that address unmet medical needs in inflammation-driven and immune dysregulation conditions.

34 employees · Israel · https://www.enlivex.com